Prostate Cancer

Phillip Lee Palmbos MD, PhD

Read more about Phillip Lee Palmbos MD, PhD

Ganesh Subramanyam Palapattu MD

Read more about Ganesh Subramanyam Palapattu MD

Ajjai Shivaram Alva MBBS

Read more about Ajjai Shivaram Alva MBBS

Megan Elizabeth Veresh Caram MD

Read more about Megan Elizabeth Veresh Caram MD

Khaled Samir Hafez MB, BCh

Read more about Khaled Samir Hafez MB, BCh

New target for prostate cancer resistant to anti-hormone therapies

Prostate cancer becomes deadly when anti-hormone treatments stop working. Now a new study suggests a way to block the hormones at their entrance.

Researchers from the University of Michigan Rogel Cancer Center have found that a protein called BET bromodomain protein 4 binds to the hormone androgen receptor downstream of where current therapies work – targeting androgen receptor signaling.

Read more about New target for prostate cancer resistant to anti-hormone therapies

Intermittent hormone therapy for prostate cancer inferior to continuous therapy

Over men 1200 men with metastatic, hormone-sensitive prostate cancer were given intermittent androgen-deprivation (AD) therapy after seven months of androgen deprivation. The results show intermittent hormone therapy offers some quality-of-life benefits, but lower overall survival.